polycythemia vera therapy

Sep 04, 2026

Summary On August 28, 2026, the FDA approved MIMRYLO (rusfertide), developed by Protagonist Therapeutics and commercialized by Takeda, for treating erythrocytosis in adults with polycythemia vera. MIMRYLO is the first approved hepcidin mimetic peptide for PV. It targets the iron-regulation pathway rather tha...

Apr 10, 2026

Summary  Three drugs that have been approved for PV include JAKAFI/JAKAVI (ruxolitinib), BESREMi (ropeginterferon alfa-2B/AOP2014/P1101), and PEGASYS (peginterferon alfa-2a). JAKAFI and BESREMi are approved in the US, Europe, and Japan, while PEGASYS is approved only in Europe. JAKAFI is nearing its pat...

Jul 10, 2025

JAKAFI’s demand continues to grow in Polycythemia Vera The therapeutic paradigm for polycythemia vera treatment has evolved notably in recent years. Historically managed with generics like aspirin, hydroxyurea, phlebotomy, and interferons, the landscape shifted dramatically with the FDA approval of JAKAFI (rux...